ArticleDiagnostics (Basel, Switzerland)2023
A Novel Hybrid Runge Kutta Optimizer with Support Vector Machine on Gene Expression Data for Cancer Classification.
Article in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 9 citations in OpenAlex.
- Identification of MAD2L1 as a novel biomarker for hepatoblastoma through bioinformatics and machine learning approaches.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
It is crucial to accurately categorize cancers using microarray data. Researchers have employed a variety of computational intelligence approaches to analyze gene expression data. It is believed that the most difficult part of the problem of cancer diagnosis is determining which genes are informative. Therefore, selecting genes to study as a starting point for cancer classification is common practice. We offer a novel approach that combines the Runge Kutta optimizer (RUN) with a support vector machine (SVM) as the classifier to select the significant genes in the detection of cancer tissues. As a means of dealing with the high dimensionality that characterizes microarray datasets, the preprocessing stage of the ReliefF method is implemented. The proposed RUN-SVM approach is tested on binary-class microarray datasets (Breast2 and Prostate) and multi-class microarray datasets in order to assess its efficacy (i.e., Brain Tumor1, Brain Tumor2, Breast3, and Lung Cancer). Based on the experimental results obtained from analyzing six different cancer gene expression datasets, the proposed RUN-SVM approach was found to statistically beat the other competing algorithms due to its innovative search technique.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.